Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116288 | 0.76 | AVPR2 (0.58) | ALDH1A1MAPTMAPK1KMT2ALMNA | |
| SCHEMBL3061025 | 0.75 | ALDH1A1 (0.68) | ALDH1A1MAPTNPSR1MAPK1KDM4E | |
| SCHEMBL4673037 | 0.75 | ALDH1A1 (0.68) | ALDH1A1MAPTNPSR1MAPK1KMT2A | |
| SCHEMBL6679959 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTNPSR1MAPK1KMT2A | |
| SCHEMBL7318907 | 0.75 | ORAI1 (0.61) | ALDH1A1MAPTNPSR1MAPK1 | |
| SCHEMBL6157961 | 0.74 | ALDH1A1 (0.71) | ALDH1A1MAPTNPSR1MAPK1KMT2A | |
| SCHEMBL6157959 | 0.74 | ALDH1A1 (0.67) | ALDH1A1MAPTNPSR1MAPK1KDM4E | |
| SCHEMBL12109904 | 0.72 | ALDH1A1 (0.53) | ALDH1A1MAPTNPSR1MAPK1KMT2A | |
| SCHEMBL7381203 | 0.71 | ALDH1A1 (0.56) | ALDH1A1MAPTNPSR1MAPK1KMT2A | |
| SCHEMBL14339571 | 0.69 | LMNA (0.62) | ALDH1A1MAPTNPSR1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009049421-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1-GANGLIOSIDOSIS/MORQUIO B DISEASE, AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | claimed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-2723384-B1 | TREATMENT OF PROTEINOPATHIES | MASSACHUSETTS GEN HOSPITAL (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9845327-B2 | Treatment of proteinopathies | THE GENERAL HOSPITAL CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140288093-A1 | TREATMENT OF PROTEINOPATHIES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2723384-A1 | TREATMENT OF PROTEINOPATHIES | The General Hospital Corporation (US) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012177997-A1 | TREATMENT OF PROTEINOPATHIES | THE GENERAL HOSPITAL CORPORATION (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2009049421-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1-GANGLIOSIDOSIS/MORQUIO B DISEASE, AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049422-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1 -GANGLIOSIDOSIS/MORQUIO B DISEASE. AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049421-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1-GANGLIOSIDOSIS/MORQUIO B DISEASE, AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049422-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1 -GANGLIOSIDOSIS/MORQUIO B DISEASE. AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288093-A1 | TREATMENT OF PROTEINOPATHIES | GAA, CTSA, GBA1 | ALDH1A1 3814/4885MAPT 114/4885NPSR1 4009/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | ALDH1A1 2142/4885MAPT 1644/4885NPSR1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.